Abstracts Archive - Page 328 of 2425 - ACR Meeting Abstracts

Abstract Number: 1519 • ACR Convergence 2023
Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis
Malcolm MacKenzie¹, Harry Atkins² and Nancy Maltez¹, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Rapidly progressive diffuse systemic sclerosis (SSc) is a devastating autoimmune disease with high morbidity and mortality. Autologous hematopoietic stem cell transplantation (AHSCT) is recognized…
Abstract Number: 1637 • ACR Convergence 2023
IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity
Helena Achten¹, Liselotte Deroo², Kristel De Boeck³, Matthias Jarlborg¹, Tine Decruy¹, Joke Deprez¹, Emilie Dumas¹, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Ghent, Belgium, ²Ghent University, Gent, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵University Hospital Ghent, Ghent, Belgium
Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…
Abstract Number: 1621 • ACR Convergence 2023
Maxillofacial MRI Augments Detection of Non-CNS Abnormalities in Pediatric Craniofacial Scleroderma
Daniel Glaser¹, Amy Metry², Elena DeRosas², Subramanian Subramanian² and Kathryn Torok³, ¹Yale University School of Medicine, New Haven, CT, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Craniofacial scleroderma is a rare subtype of linear scleroderma affecting the head and neck. Up to 40% of patients experience extracutaneous manifestations (ECMs), but…
Abstract Number: 1646 • ACR Convergence 2023
The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis
Keren Port¹, Ivan Ho Shon¹, Sally Ayesa¹, Rachel Langford¹, Olivia Bennett¹, Andrew Csillag¹, Stacey Fredericks¹, Luz Palacios-Derflingher², Eva Wegner¹ and Anthony Sammel¹, ¹The Prince of Wales Hospital, Sydney, Australia, ²University of New South Wales, Sydney, Australia
Background/Purpose: GCA is a systemic medium-large vessel vasculitis (M-LVV) involving the cranial arteries, aorta and its major branches. Recent studies have shown that PET/CT including…
Abstract Number: 1221 • ACR Convergence 2023
Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)
Albert Chow¹, Sean Koester², Evan Pepper-Tunick³, Peggy Lee⁴, Mary Eckert⁵, Laurie Brenchley⁶, Pamela Gardner⁶, Naisi Li², adam Schiffenbauer⁷, Rita Volochayev⁷, Nastaran Bayat⁸, Jeffrey McLean⁹, Lisa Rider¹⁰, Susan Shenoi¹¹, Anne Stevens¹² and Neelendu Dey¹³, ¹Loma Linda University, Loma Linda, CA, ²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, ³Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, ⁴Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, ⁵Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, ⁶Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁸Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁹Department of Periodontics, University of Washington, Seattle, WA, ¹⁰NIEHS, NIH, Bethesda, MD, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²Janssen, Hansville, WA, ¹³Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA
Background/Purpose: JDM is a rare immune-mediated disease of childhood that is thought to result from genetic predisposition and environmental drivers, with documented links to microbial…
Abstract Number: 1645 • ACR Convergence 2023
Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort
Anthony Sammel¹, Ivan Ho Shon², Daniel Moses¹, Fredericks Stacey¹, Gita Mathur¹, Claudia Hillenbrand³, Edward Hsiao⁴, Schembri Geoffrey⁴, Rodger Laurent⁴ and Eva Wegner², ¹Prince of Wales Hospital, Randwick, Australia, ²The Prince of Wales Hospital, Sydney, Australia, ³University of NSW, Randwick, Australia, ⁴Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: Aortic dilatation is typically a late complication of giant cell arteritis (GCA) but there are no tools to risk stratify patients at the time…
Abstract Number: 1617 • ACR Convergence 2023
Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022
Eric Roberts¹, Jing Li¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski¹, Gabriela Schmajuk⁴ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, HI, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: The first infliximab biosimilar (infliximab-dybb) entered the U.S. market in 2016, and two additional products have subsequently been introduced (infliximab-axxq (2017) and infliximab-abda (2020)).…
Abstract Number: 1657 • ACR Convergence 2023
Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution
Gabrielle Rabadam¹, Camilla Wibrand², Emily Flynn¹, George Hartoularos¹, Yang Sun¹, Susan Kim³, Chun Jimmie Ye¹, Zev Gartner¹, Marina Sirota⁴ and Jessica Neely¹, ¹University of California San Francisco, San Francisco, CA, ²Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, ³UCSF Benioff Children's Hospital, San Francisco, CA, ⁴Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare multisystem autoimmune condition that involves complex immune responses in both innate and adaptive compartments. Currently, we have a…
Abstract Number: 1246 • ACR Convergence 2023
Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Belina Yi¹, Dawn Wahezi², Lauren Covert³, Kaveh Ardalan⁴, Joyce Hui-Yuen⁵, Natalia Vasquez Canizares⁶, Doaa Mosad Mosa⁷, Madison Jones⁸, Colleen Correll⁹, Alexis Begezda¹⁰, Susan Shenoi¹¹, Eveline Wu¹², Leonard Kovalick¹³, William Lapin¹⁴, Stacey Tarvin¹⁵, Melissa Oliver¹⁶, Martha Rodriguez¹⁷, Itay Marmor¹⁸, Kevin Baszis¹⁹, Alysha Taxter²⁰, Andrew Hanson²¹, Cynthia Crowson²² and Amir Orandi²², ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Duke University, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵North Shore LIJ Health System, Great Neck, NY, ⁶Children's Hospital at Montefiore, New York, NY, ⁷Mansoura University Hospitals, Mansoura University Faculty of Medicine, Mansoura city, Egypt, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁹University of Minnesota, Minneapolis, MN, ¹⁰Penn State, Hummelstown, PA, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²University of North Carolina School of Medicine, Chapel Hill, NC, ¹³UNC Health Care, Durham, NC, ¹⁴Connecticut Children's, Hartford, CT, ¹⁵Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ¹⁶Indiana University, Indianapolis, IN, ¹⁷Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁸Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ¹⁹Washington Univ in St. Louis School of Medicine, St. Louis, MO, ²⁰Nationwide Children's, Columbus, OH, ²¹Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ²²Mayo Clinic, Rochester, MN
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…
Abstract Number: 1223 • ACR Convergence 2023
Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis
Carla Levin¹, Andrea Ontaneda², Danielle Guffey³, Peter Rycus⁴, Marc Anders², Eyal Muscal⁵ and Maria Pereira⁵, ¹Department of Pediatrics, Baylor College of Medicine, Houston, TX, ²Division of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ³Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, ⁴Extracorporeal Life Support Organization, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous multisystemic autoimmune disorder that can cause life-threatening complications. There is a paucity of data on the utility…
Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Kaleb Michaud¹, Sofia Pedro², Shreena Kamlesh Gandhi³ and Frederick Wolfe², ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Kansas University School of Medicine, Wichita, KS
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
Abstract Number: 1552 • ACR Convergence 2023
Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France
Benjamin Terrier¹, Camille Taillé², Alice Brouquet³, Solenne Tauty³, Francoise Bugnard³, Loic Guillevin⁴, Xavier Puéchal⁵ and Vincent Cottin⁶, ¹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ³Steve Consultant, Lyon, France, ⁴University Paris Descartes, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁶Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) belongs to the group of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). There are no recent data on…
Abstract Number: 1419 • ACR Convergence 2023
Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
Peter Nash¹, Iain McInnes², Christopher T. Ritchlin³, Lai-Shan Tam⁴, Enrique Soriano⁵, Michael Starr⁶, Emmanouil Rampakakis⁷, Frederic Lavie⁸, May Shawi⁹, Xenofon Baraliakos¹⁰ and Philip J. Mease¹¹, ¹School of Medicine, Griffith University, Brisbane, Australia, ²University of Glasgow, Glasgow, United Kingdom, ³University of Rochester Medical Center, Department of Medicine – Allergy/Immunology and Rheumatology, Rochester, NY, ⁴The Chinese University of Hong Kong, New Territories, China, ⁵Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Division of Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁷McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹Immunology, Janssen Research & Development, LLC, Titusville, NJ, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Pain in PsA has multifaceted origins (e.g., peripheral joint inflammation, axial involvement [axPsA], skin lesions, dactylitis, enthesitis, underlying conditions) and can be difficult to…
Abstract Number: 1209 • ACR Convergence 2023
The Role of Kinesiophobia on Ankylosing Spondylitis Disease Activity, Exercise Habits, and Quality of Life
Joel Thompson, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Patients with Ankylosing Spondylitis (AS) consistently report exercise frequencies that are lower than healthy controls and ACSM/EULAR recommended frequencies; even though exercise has consistently…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].